Logging out of EU Login will log you out of any other services that use your EU Login account. Use the CORDIS log out button to remain logged in on other services.
This is a machine translation provided by the European Commission’s eTranslation service to help you understand this page. Please read the conditions of use.
Utility of tumor antigens as therapeutic and diagnostic tools
Final Activity Report Summary - LUNGCAABS (Utility of tumor antigens as therapeutic and diagnostic tools)
The project aimed the characterisation of naturally occurring immune responses against tumours elicited by the host (patient). We successfully showed that an immune response against the tumour-associated protein SOX2, associates with longer survival in patients with small cell lung cancer. Most importantly, we showed that this response is an independent prognostic criteria indicating that regardless of the patient's clinical state, the presence of antibodies is a marker for longer survival. These results have important implications for immunotherapy for small cell lung cancer patients.